During the past decade, Ordensklinikum Linz GmbH Elisabethinen conducted 132 clinical trials. In the 10-year time frame, 132 clinical trials started and 37 clinical trials were completed, i.e. on average, 28% percent of trials that started reached the finish line to date. In the past 5 years, 74 clinical trials started and 29 clinical trials were completed. i.e. 39.2% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Ordensklinikum Linz GmbH Elisabethinen" #1 sponsor was "Celgene" with 9 trials, followed by "University of Ulm" with 9 trials sponsored, "Pfizer" with 8 trials sponsored, "Amgen" with 7 trials sponsored and "Arbeitsgemeinschaft medikamentoese Tumortherapie" with 7 trials sponsored. Other sponsors include 148 different institutions and companies that sponsored additional 90 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Ordensklinikum Linz GmbH Elisabethinen" #1 collaborator was "Hoffmann-La Roche" with 4 trials as a collaborator, "Merck Sharp & Dohme LLC" with 4 trials as a collaborator, "Astellas Pharma Inc" with 3 trials as a collaborator, "Bristol-Myers Squibb" with 3 trials as a collaborator and "Incyte Corporation" with 3 trials as a collaborator. Other collaborators include 99 different institutions and companies that were collaborators in the rest 95 trials.

According to Clinical.Site data, the most researched conditions in "Ordensklinikum Linz GmbH Elisabethinen" are "Acute Myeloid Leukemia" (11 trials), "Breast Cancer" (7 trials), "Multiple Myeloma" (7 trials), "Pulmonary Arterial Hypertension" (6 trials) and "Atrial Fibrillation" (5 trials). Many other conditions were trialed in "Ordensklinikum Linz GmbH Elisabethinen" in a lesser frequency.

Most popular intervention types in "Ordensklinikum Linz GmbH Elisabethinen" are "Drug" (152 trials), "Biological" (20 trials), "Device" (15 trials), "Other" (10 trials) and "Procedure" (7 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (40 trials), "Gemcitabine" (10 trials), "Cytarabine" (8 trials), "Pembrolizumab" (8 trials) and "Docetaxel" (7 trials). Other intervention names were less common.

The vast majority of trials in "Ordensklinikum Linz GmbH Elisabethinen" are 165 trials for "All" genders, 16 trials for "Male" genders and 12 trials for "Female" genders.

Currently, there are 97 active trials in "Ordensklinikum Linz GmbH Elisabethinen". 1 are not yet recruiting, 53 are recruiting, 42 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 73 completed trials in Ordensklinikum Linz GmbH Elisabethinen, undefined suspended trials, and 13 terminated clinical trials to date.

Out of the total trials that were conducted in Ordensklinikum Linz GmbH Elisabethinen, 15 "Phase 1" clinical trials were conducted, 47 "Phase 2" clinical trials and 107 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 9 trials that are defined as “Not Applicable".

Ordensklinikum Linz GmbH Elisabethinen has several departments that took part in Clinical trials: "Ordensklinikum Linz Barmherzige Schwestern; Abt. fur Innere Medizin 1" - 8 trials, "BHS Linz: Interne I: Internistische Onkologie, Hämatologie und Gastroenterologie" - 6 trials, "Ordensklinikum Linz Elisabethinen; Abteilung für Urologie und Andrologie" - 4 trials, "Department of gynaecology, Ordensklinikum Linz Ges.m.b.H, Barmherzige Schwestern" - 2 trials, "Hospital BHS Linz, Radiooncology" - 2 trials, "Ordensklinikum Linz Barmherzige Schwestern Interne I" - 2 trials